Efficacy of Mirazid in Comparison With Praziquantel in Egyptian Schistosoma Mansoni–infected School Children and Households

Abstract

This trial investigated the anti-schistosomal activity of mirazid in comparison with that of praziquantel in Schistosoma mansoni-infected Egyptian patients. The sample population was composed of 1,131 individuals (459 school children and 672 household members). Screening for S. mansoni was conducted using the standard Kato Katz technique. Four slides from a single stool sample were examined before treatment, and four slides per sample from stool samples obtained on three consecutive days were examined post-treatment. All positive eligible subjects were randomly assigned into two groups, the first received mirazid at a dose of 300 mg/day for three consecutive days, and the second received praziquantel at a single dose of 40 mg/kg. All treated subjects were examined 4-6 weeks post-treatment. Mirazid showed low cure rates of 9.1% and 8.9% in S. mansoni-infected school children and household members, respectively, compared with cure rates of 62.5% and 79.7%, respectively, in those treated with praziquantel. Therefore, we do not recommend mirazid as an agent to control schistosomiasis.

Efficacy and Safety of Arachidonic Acid for Treatment of Schistosoma mansoni-Infected Children in Menoufiya, Egypt

“…[36][37][38][39][40] ARA seemed a far more promising schistosomicidal remedy than myrrh (Mirazid), which showed a low (10-15%) cure rate and low egg reductions in uncured individuals, regardless of the patients' ages or pre-treatment intensities of infection. [41][42][43] Despite that a 100% cure was reported after PZQ treatment of S. mansoni infections in eastern Sudan, 44 complete cures have seldom, if ever, been achieved in endemic areas after PZQ treatment. 45 Notably, 100% cure was also not achieved, even in children treated with a combination of PZQ and ARA, because two children still passed eggs.…”

Further assessment of Mirazid as antischistosomal drug in experimental schistosomiasis hematobium

“…These authors claimed that they cannot recommend the use of MZ for treatment of human schistosomiasis. MZ was also used for the treatment of S. mansoni infected Egyptian patients by Botros et al (2005) and very low cure rates were found (9.1% and 8.9% in S. mansoni infected school children and household members), compared with 62.5% and 79.6% cure rate in those treated with praziquantel, respectively. Barakat et al (2005) studied the effect of MZ on human schistosomiasis mansoni and found that the cure rate was very low after one treatment (15.6%) and much less (8.9%) by another treatment.…”

“…On the other hand, Botros et al (2005) found that MZ has a much lower cure rate, 9.1% and 8.9% in school children and household members, compared with 62.5% and 79.6%, in those treated with praziquantel respectively. Similarly, Barakat et al (2005) studied the effect of this drug on human schistosomiasis mansoni and found that the cure rate of MZ was 15.6% after one treatment and 8.9% after a second one.…”

Effect of Chemotherapy with Praziquantel on the Production of Cytokines and Morbidity Associated with Schistosomiasis Mansoni

“…The drug is safe and has a high efficacy against both trematodes and cestodes (9,11). Furthermore, there is evidence that treatment with praziquantel induces a change in the immune response that provides partial protection against schistosome infection, thus providing benefits that may extend beyond a transient reduction in levels of infection (21,40,42).…”